603127 昭衍新藥
按盤價 
33.970 -1.470 (-4.148%) | 2025/06 - 中期 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 0.753 | 0.906 | 4.823 | 14.024 | 13.335 |
| 總資產報酬率 ROA (%) | 0.646 | 0.763 | 3.894 | 11.367 | 10.474 |
| 投入資產回報率 ROIC (%) | 0.668 | 0.790 | 4.089 | 11.932 | 11.017 | 邊際利潤分析 |
| 銷售毛利率 (%) | 24.027 | 28.428 | 42.617 | 47.898 | 48.733 |
| 營業利潤率 (%) | 11.944 | 5.170 | 21.338 | 54.041 | 42.388 |
| 息稅前利潤/營業總收入 (%) | 6.387 | 0.211 | 14.974 | 47.854 | 41.067 |
| 淨利潤/營業總收入 (%) | 9.114 | 3.456 | 16.476 | 47.320 | 36.686 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 1.474 | 244.702 | 148.826 | 68.484 | 66.931 |
| 價值變動淨收益/利潤總額(%) | 149.969 | -87.503 | -46.556 | 29.241 | 27.224 |
| 營業外收支淨額/利潤總額(%) | 0.330 | -0.296 | -0.029 | 1.158 | -0.138 | 償債能力分析 |
| 流動比率 (X) | 4.524 | 4.530 | 4.854 | 3.215 | 4.789 |
| 速動比率 (X) | 3.186 | 3.199 | 3.584 | 2.025 | 4.212 |
| 資產負債率 (%) | 14.445 | 14.016 | 17.414 | 20.970 | 16.313 |
| 帶息債務/全部投入資本 (%) | 9.281 | 8.792 | 11.435 | 12.762 | 11.421 |
| 股東權益/帶息債務 (%) | 953.831 | 1,011.605 | 749.269 | 657.404 | 757.156 |
| 股東權益/負債合計 (%) | 592.277 | 613.442 | 474.155 | 376.548 | 512.423 |
| 利息保障倍數 (X) | -1.141 | -0.043 | -2.355 | -7.016 | -32.515 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 45.812 | 34.530 | 30.710 | 24.369 | 23.317 |
| 存貨周轉天數 (天) | 538.566 | 416.385 | 535.589 | 441.019 | 256.218 |
| 備註： | 即時報價更新時間為 11/09/2025 09:51 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
